BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Friday, September 11, 2026
📌TL;DR
The FDA placed a partial clinical hold on Biohaven's pivotal opakalim (BHV-7000) epilepsy program on September 10, pausing new enrollment over a rodent metabolite finding; RISE 3, fully enrolled since June, is unaffected and its topline is still expected in 2026. BHVN closed down 14.7 percent.
David Samra of Artisan Partners, a top 20 Novartis shareholder per Reuters, called for board level changes after the del-desiran, pelacarsen, and pelabresib setbacks; Novartis called its capital allocation disciplined and left guidance unchanged.
The surrogate discount week closed with NVS down 14.1 percent and AMGN down 12.5 percent from the September 4 close, per official exchange closes; AMGN fell a further 2.2 percent Thursday with no company disclosure.
Axogen agreed to buy BioCircuit Technologies for $200 million in cash, adding NerveTape, the first FDA approved device for sutureless peripheral nerve repair; AXGN fell 11.5 percent on the equity funded deal.
Frazier Life Sciences closed a $1.1 billion public markets fund; BioSpace counted August biopharma layoffs at just over 500 people, down 90 percent year over year.
Takeda R&D chief Andy Plump will retire after eleven years, staying on until a successor is named.
⚡ Executive Takeaway
We set this week's job on Tuesday: watch whether the market's new discount on surrogate promises holds once the shock fades. It held, and then it grew teeth. The tape part is arithmetic. The interesting part is that by Thursday the cost of a failed surrogate bet had migrated from the ticker to the boardroom, when a major holder told the Novartis chairman, in public, through Reuters, that the board itself is the problem.
That migration is the week's real close. A repricing that lives only in stock charts fades when the tape turns. A repricing with a board campaign attached changes behavior: every large cap business development committee now knows a biomarker premium that fails does not just cost the stock a seventh of its value, it invites a public argument about who approved it. Fifteen days from de risking deal to enrollment hold at Biohaven made the same point from the other direction, on the same day. The discount now has enforcement, and enforcement is what makes a discount durable.
🧠 Neuro
The FDA arrived fifteen days after Biohaven's de risking deal. BHVN
The agency placed a partial clinical hold on the pivotal opakalim (BHV-7000) focal epilepsy program, pausing new enrollment while it reviews a metabolite finding from rodent studies. Dosing continues for enrolled patients, and RISE 3, fully enrolled since June, is unaffected with its topline still expected this year; RISE 2 recruitment stops and its December completion target likely slips. Biohaven says the finding may be rodent specific and not relevant to human safety, and it disclosed the hold in a filing rather than a release. The sting is the sequence: SK Biopharmaceuticals licensed the whole Kv7 platform on August 26 for up to $795 million, with all data, the metabolite package included, reviewed before signing. The stock closed at $12.79, down 14.7 percent.
🏛️ Governance
A top 20 shareholder just made Novartis' misses a board problem. NVS
David Samra, a managing director at Artisan Partners, urged chairman Giovanni Caforio to change the board over dealmaking oversight, telling Reuters the record has been "uninspiring at best." The bill of particulars is the one we have tracked all week: del-desiran, from the $12 billion Avidity acquisition, missed its Phase 3; pelacarsen failed its 8,323 patient outcomes trial; pelabresib, from the $2.9 billion MorphoSys deal, sits behind safety signals and a delayed filing, per Reuters. Novartis called its capital allocation disciplined and shareholder friendly and left guidance unchanged. NVS closed unchanged at $137.48, down 14.1 percent on the week.
📊 The Tally
The surrogate discount held all week, everywhere we tracked it. NVS | AMGN | RPRX | NVO | IONS | GENB | AZN
From the September 4 close through Thursday, per official exchange closes: NVS down 14.1 percent, AMGN down 12.5, RPRX down 8.1, GENB down 6.1, NVO down 5.6, IONS down 4.2, AZN down 1.9. Nothing round tripped. Amgen kept falling Thursday, down another 2.2 percent with no company disclosure, and the first dated venue for an olpasiran answer is now on the calendar: management presents at Morgan Stanley on Tuesday, September 15. None of the week's four withheld datasets acquired a congress date. The only withheld number with a due date is still Boston Scientific's October 28 guidance revision.
🩻 Medtech
Axogen paid $200 million to retire the microsuture. AXGN
Axogen will acquire BioCircuit Technologies for $200 million in cash, picking up NerveTape, the first FDA approved device for sutureless peripheral nerve repair. Microsuturing is the skill bottleneck in nerve repair; a device that removes it widens who can do the procedure, which is the whole volume thesis. BioCircuit's electronics arm spins out first, the deal closes in the fourth quarter, and Axogen calls it accretive in year one. The market's issue was the check: a concurrent equity offering funds the purchase, and AXGN fell 11.5 percent to $41.85.
💰 Capital Markets
A billion for public biotech, and layoffs down 90 percent.
Frazier Life Sciences closed $1.1 billion for its public fund, per the firm's announcement, bringing the vehicle to $2.8 billion raised since 2021; it takes long positions in small and mid cap public biotechs and joins late stage crossovers. The same day, BioSpace counted August biopharma layoffs at just over 500 people, down 90 percent year over year, while Massachusetts Governor Maura Healey told industry leaders capital is still harder to come by. All three are true at once: the barbell keeps sharpening, with public and late stage money abundant, Tuesday's $550 million private day included, while earlier stories scrape. ADARx's IPO, filed September 4, and Oura's are the next pricing tests.
🧬 People
Takeda's Andy Plump era in R&D is ending. TAK
Plump, chief of R&D since arriving from Sanofi in 2015, will retire and stays on until a successor is named, per Fierce Biotech. The scorecard spans Orzeyful and Mimrylo, both approved last month, positive Phase 3 zasocitinib data, and Livtencity, Adzynma, and Eohilia, set against the cell therapy exit and Alofisel's Phase 3 failure. Succession at one of the industry's largest R&D organizations becomes an open question in the same season the FDA settled its own leadership. TAK ADRs closed at $18.11.
📋 Quick Hits
Lonza will add a commercial spray drying facility at its Bend, Oregon site, extending the US onshoring wave; Endpoints separately reported a $262 million Samsung Biologics manufacturing contract, client unnamed in the reporting we could verify.
Shionogi's stroke candidate failed a mid stage trial, per Endpoints; Tyra Biosciences slipped after bladder cancer responses fell short of investor expectations, per BioSpace; BridgeBio Oncology narrowed its KRAS program's scope.
An industry survey called the MFN pricing environment a policy earthquake, with drugmakers cherry picking launch regions, per BioSpace and Fierce Pharma coverage.
The FDA signaled regulatory flexibility on psychedelics, per Endpoints, ahead of Definium's Panorama generalized anxiety topline due this month.
Amylyx logged a ninth consecutive close below its $35.50 offer price at $32.09; the $500.2 million offering's closing remained unannounced as of Thursday evening, with greenshoe mechanics forcing disclosure by roughly September 18 and a Morgan Stanley appearance Tuesday.
Heidi Overton's confirmation hearing remains unscheduled, and the Lilly purchase of Sangamo's platforms, expected to close September 4, was still unconfirmed as of Thursday evening.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The RISE program table: what the partial hold stops, what continues, and which dates moved
The Novartis setback ledger, every figure traced to its source
The full seven ticker surrogate discount week table, September 4 to September 10 closes
The dated catalyst slate through the newly primary verified December 23 anito-cel action date
📋 The Week in Review
Monday: US markets closed for Labor Day; the pelacarsen Lp(a)HORIZON failure and Novo's two ziltivekimab halts led Tuesday's edition and set the week's through line on the surrogate discount.
Tuesday: Amgen fell 10.1 percent on olpasiran readacross; three sponsors issued numberless late stage toplines in one day, del-desiran, DeLLphi-305, and arlo-cel; the FDA approved AstraZeneca's Etcamah and made Michael Davis and Karim Mikhail permanent at CDER and CBER.
Wednesday: Bayer's Hyrnuo won first line accelerated approval on a 75 percent response rate; Solstice, Encoded, and Caspian raised a combined $550 million in a day; BioMarin's Voxzogo hypochondroplasia data published with its FDA filing submitted.
Thursday: the FDA paused Biohaven's opakalim enrollment; Artisan Partners demanded Novartis board changes; Axogen agreed to buy BioCircuit for $200 million; Frazier closed $1.1 billion; the surrogate discount week ended with nothing round tripped.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The tally has a second column: which of the seven discounted tickers actually de rated versus merely fell, and the single Tuesday test that says whether the discount survives conference season
💊 SK read the metabolite data and paid $350 million anyway: the three scenarios for the Biohaven hold, the one readout that adjudicates them, and what each does to the Kv7 platform's value
📊 Governance is now a catalyst class: what Artisan's demand does to every biomarker premium sitting on a board agenda this fall, and the deal structure that gets funded instead
🎯 Plus the full catalyst calendar, updated with a newly primary verified December 23 anito-cel action date and Tuesday's Morgan Stanley double bill
The week began with a failed outcomes trial and ended with a shareholder naming the board. In between, nothing round tripped. We will be back Monday with the weekend swept. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →